Abbisko Cayman (SEHK:2256) Stock Valuation, Peer Comparison & Price Targets

Share Price vs Fair Value

What is the Fair Price of 2256 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 2256's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 2256's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 2256?

Key metric: As 2256 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 2256. This is calculated by dividing 2256's market cap by their current revenue.
What is 2256's PS Ratio?
PS Ratio	4.8x
Sales	CN¥497.27m
Market Cap	CN¥2.38b

2256 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	4.1x
Enterprise Value/EBITDA	-68x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 2256's PS Ratio compare to its peers?

The above table shows the PS ratio for 2256 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	12.2x
2487 Cutia Therapeutics	12x	41.4%	HK$2.6b
2315 Biocytogen Pharmaceuticals (Beijing)	2.8x	22.4%	HK$2.4b
2616 CStone Pharmaceuticals	5.1x	34.3%	HK$2.5b
2509 Qyuns Therapeutics	28.9x	n/a	HK$1.9b
2256 Abbisko Cayman	4.8x	8.8%	HK$2.6b

Price-To-Sales vs Peers: 2256 is good value based on its Price-To-Sales Ratio (4.8x) compared to the peer average (12.2x).

Price to Sales Ratio vs Industry

How does 2256's PS Ratio compare vs other companies in the HK Biotechs Industry?

14 Companies	Price / Sales	Estimated Growth	Market Cap
6826 Shanghai Haohai Biological Technology	2.2x	11.8%	US$1.89b
1530 3SBio	1.5x	9.2%	US$1.74b
2696 Shanghai Henlius Biotech	1.8x	10.4%	US$1.42b
775 CK Life Sciences Int'l. (Holdings)	0.8x	n/a	US$549.50m

14 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: 2256 is good value based on its Price-To-Sales Ratio (4.8x) compared to the Hong Kong Biotechs industry average (11.7x).

Price to Sales Ratio vs Fair Ratio

What is 2256's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

2256 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	4.8x
Fair PS Ratio	2.3x

Price-To-Sales vs Fair Ratio: 2256 is expensive based on its Price-To-Sales Ratio (4.8x) compared to the estimated Fair Price-To-Sales Ratio (2.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 2256 forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	HK$4.10	HK$9.20 +124.3%	58.4%	HK$18.00	HK$3.59	n/a	4
Nov ’25	HK$4.31	HK$8.78 +103.6%	60.0%	HK$16.00	HK$3.60	n/a	3
Oct ’25	HK$3.86	HK$8.78 +127.4%	60.0%	HK$16.00	HK$3.60	n/a	3
Sep ’25	HK$3.14	HK$8.78 +179.5%	60.0%	HK$16.00	HK$3.60	n/a	3
Aug ’25	HK$3.00	HK$8.78 +192.6%	60.0%	HK$16.00	HK$3.60	n/a	3
Jul ’25	HK$3.25	HK$8.72 +168.2%	59.7%	HK$15.84	HK$3.57	n/a	3
Jun ’25	HK$3.17	HK$8.20 +158.6%	56.5%	HK$15.93	HK$3.59	n/a	4
May ’25	HK$3.30	HK$8.20 +148.4%	56.5%	HK$15.93	HK$3.59	n/a	4
Apr ’25	HK$2.88	HK$8.20 +184.6%	56.5%	HK$15.93	HK$3.59	n/a	4
Mar ’25	HK$2.66	HK$7.84 +194.6%	54.0%	HK$15.99	HK$3.65	n/a	5
Feb ’25	HK$2.34	HK$7.89 +237.1%	54.7%	HK$16.22	HK$3.66	n/a	5
Jan ’25	HK$3.65	HK$7.89 +116.1%	54.7%	HK$16.22	HK$3.66	n/a	5
Dec ’24	HK$4.26	HK$7.34 +72.3%	64.4%	HK$16.34	HK$3.26	n/a	5
Nov ’24	HK$2.90	HK$7.33 +152.7%	70.9%	HK$16.05	HK$3.20	HK$4.31	4
Oct ’24	HK$2.67	HK$7.33 +174.5%	70.9%	HK$16.05	HK$3.20	HK$3.86	4
Sep ’24	HK$2.38	HK$7.86 +230.3%	61.5%	HK$16.04	HK$3.54	HK$3.14	4
Aug ’24	HK$2.82	HK$6.85 +142.9%	64.4%	HK$15.36	HK$3.35	HK$3.00	5
Jul ’24	HK$2.68	HK$7.62 +184.4%	63.4%	HK$15.83	HK$3.32	HK$3.25	4
Jun ’24	HK$2.74	HK$7.62 +178.1%	63.4%	HK$15.83	HK$3.32	HK$3.17	4
May ’24	HK$2.95	HK$7.67 +160.1%	64.1%	HK$16.03	HK$3.36	HK$3.30	4
Apr ’24	HK$2.95	HK$7.67 +160.1%	64.1%	HK$16.03	HK$3.36	HK$2.88	4
Mar ’24	HK$3.06	HK$8.75 +185.8%	57.6%	HK$15.92	HK$3.14	HK$2.66	5
Feb ’24	HK$3.36	HK$9.10 +170.8%	58.3%	HK$16.90	HK$3.20	HK$2.34	5
Jan ’24	HK$3.21	HK$10.07 +213.7%	38.4%	HK$15.87	HK$5.59	HK$3.65	5
Dec ’23	HK$3.72	HK$10.07 +170.7%	38.4%	HK$15.87	HK$5.59	HK$4.26	5
Nov ’23	HK$2.85	HK$9.02 +216.6%	34.4%	HK$12.93	HK$5.01	HK$2.90	5

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

China Shineway Pharmaceutical Group

HK$6.3b

An investment holding company, engages in the research and development, manufacture, and trade of Chinese medicines in the People’s Republic of China and Hong Kong.

2877

HK$8.28

7D

-5.9%

1Y

n/a

China Shineway Pharmaceutical Group

HK$6.3b

An investment holding company, engages in the research and development, manufacture, and trade of Chinese medicines in the People’s Republic of China and Hong Kong.

2877

HK$8.28

7D

-5.9%

1Y

n/a

Innovent Biologics

HK$58.9b

A biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in the People’s Republic of China.

1801

HK$35.90

7D

-4.9%

1Y

-18.1%

Abbisko Cayman Valuation